Holen Sie sich die Stockscreener-App
1.22
1.61%
-0.02
Handel nachbörslich:
1.25
0.03
+2.46%
Inmune Bio Inc Aktie (INMB) Neueste Nachrichten
INMB Showcases Advancements in Alzheimer's Treatment at AD/PD 20 - GuruFocus
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease - The Manila Times
Alzheimer’s trial gets plenary spotlight as blood markers guide treatment - Stock Titan
INMB stock rises pre-market – what did the FDA say about its Alzheimer’s trial? - MSN
Rally Mode: Whats the profit margin of INmune Bio IncTrade Exit Report & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Market Outlook: Is INmune Bio Inc stock undervalued right nowPortfolio Risk Summary & Accurate Buy Signal Notifications - baoquankhu1.vn
Setup Watch: How liquid is INmune Bio Inc stockTrade Entry Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Gainers Report: How does INmune Bio Inc compare to its peersWeekly Trade Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Will INmune Bio Inc benefit from geopolitical trends2026 Momentum & Free Community Supported Trade Ideas - baoquankhu1.vn
INmune Bio Inc Stock (ISIN: US45764T1060) Faces Analyst Hold Consensus Amid $8 Price Target - AD HOC NEWS
INmune Bio Receives $8 Consensus Price Target from Analysts - National Today
INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by Lucid Cap Mkts - Defense World
Lucid Capital Markets upgrades INmune Bio (INMB) - MSN
INMB Stock Receives Major Upgrade from Lucid Capital Markets | I - GuruFocus
Lucid Capital Markets upgrades INmune Bio stock rating on RDEB therapy - Investing.com
INmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of “Reduce” by Analysts - Defense World
INMB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sentiment Watch: Whats the RSI of INmune Bio Inc stockBreakout Watch & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Breakout Zone: Is INmune Bio Inc stock undervalued right nowMarket Movers & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Aug Wrap: What is the earnings history of INmune Bio IncJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
INMB Stock Gained 3% Today – What Did The FDA Say About Its Alzheimer’s Trial? - Stocktwits
Aug Intraday: Is CRBG undervalued by DCF analysisWeekly Earnings Recap & Weekly Momentum Picks - baoquankhu1.vn
Inmune Bio (INMB): Why This Beaten-Down Small-Cap Is Back on Risk Radars - AD HOC NEWS
INMB Technical Analysis & ETF Price Forecast - Intellectia AI
Inmune Bio Completes Early INKmune Trial in Advanced Prostate Cancer: What Investors Should Watch Next - TipRanks
INmune Bio Highlights CORDStrom RDEB Program and IP Strength - TipRanks
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
Inmune Bio, Inc. advances therapies for rare disease impact beyond skin - Traders Union
INmune Bio Announces Upcoming Webinar on New RDEB Treatment Data - National Today
INMB.O Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Decliners: What is the earnings history of INmune Bio IncJuly 2025 Big Picture & Expert Verified Stock Movement Alerts - baoquankhu1.vn
INmune Bio Advances XPro Toward Registrational Alzheimer’s Study - TipRanks
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar - The Manila Times
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Levels Update: Is INmune Bio Inc stock undervalued right nowMarket Sentiment Review & Daily Stock Trend Reports - baoquankhu1.vn
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB - The Manila Times
INmune Bio to host webinar on RDEB treatment data - Investing.com Australia
INmune Bio to Present New CORDStrom Phase III Data - TipRanks
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
CORDStrom Phase III RDEB data to be detailed by INmune Bio (NASDAQ: INMB) - Stock Titan
INmune Bio to host webinar on RDEB treatment data By Investing.com - Investing.com Nigeria
INmune Bio Inc. to Host Webinar on CORDStrom Treatment for Recessive Dystrophic Epidermolysis Bullosa, Highlighting New Clinical Data and Insights from MissionEB Study - Quiver Quantitative
New trial data on systemic treatment for a painful skin disease - Stock Titan
Aug Action: What are INmune Bio Incs earnings expectations2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
INMB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Is INmune Bio Inc. stock a buy for dividend growthPortfolio Growth Summary & Technical Analysis for Trade Confirmation - mfd.ru
INmune Bio Advances CORDStrom Toward Rare Disease Commercialization - TipRanks
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
Inmune Bio plans to seek approval of RDEB treatment in UK, US, and EU in 2026 - Epidermolysis Bullosa News
Inmune Bio announces FDA alignment on integrated Phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
Inmune Bio announces FDA alignment on integrated phase 2B/3 registration pathway for Xpro1595 in early Alzheimer's disease - marketscreener.com
INMB Stock Rises Pre-Market – What Did The FDA Say About Its Alzheimer’s Trial? - Asianet Newsable
1.20%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):